Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bendazac→

Bendazac Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
20187-55-7
Molecular formula
C16H14N2O3
Molecular weight
282.29 g/mol
Drug class
Non-steroidal anti-inflammatory drugtopical or ophthalmic phenylacetic acid derivative
Mechanism of action
Has local anti-inflammatory effects and may inhibit prostaglandin-related inflammatory pathways; the precise molecular mechanism in ophthalmic products is not fully characterised.
Indications / reported uses
  • Historically used in some countries as an ophthalmic preparation for selected cataract-related conditions and as a topical anti-inflammatory agent; current availability and efficacy claims require jurisdiction-specific verification

Sources: NLM MeSH — Bendazac · PubMed — Bendazac ophthalmic pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bendazac Environmental Risk Assessment (ERA) (the Bendazac ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.